AR117191A1 - Composiciones inmunogénicas - Google Patents
Composiciones inmunogénicasInfo
- Publication number
- AR117191A1 AR117191A1 ARP190103212A ARP190103212A AR117191A1 AR 117191 A1 AR117191 A1 AR 117191A1 AR P190103212 A ARP190103212 A AR P190103212A AR P190103212 A ARP190103212 A AR P190103212A AR 117191 A1 AR117191 A1 AR 117191A1
- Authority
- AR
- Argentina
- Prior art keywords
- present
- immunogenic compositions
- vme
- patient
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente proporciona una composición inmunogénica que comprende VME y (a) antígeno acelular de la tos ferina, (b) un toxoide tetánico y (c) un toxoide diftérico, en la que las VME se obtienen de Bordetella pertussis. La presente también proporciona composiciones para su uso en un procedimiento de aumento de la respuesta inmunitaria en un paciente, que comprende la etapa de administrar al paciente una composición de la presente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18204691 | 2018-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR117191A1 true AR117191A1 (es) | 2021-07-21 |
Family
ID=64456746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190103212A AR117191A1 (es) | 2018-11-06 | 2019-11-04 | Composiciones inmunogénicas |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230201325A1 (es) |
EP (1) | EP3876982A1 (es) |
JP (1) | JP7469302B2 (es) |
KR (1) | KR20210090646A (es) |
CN (1) | CN112996538A (es) |
AR (1) | AR117191A1 (es) |
AU (1) | AU2019376832B2 (es) |
BR (1) | BR112021007668A2 (es) |
CA (1) | CA3117867A1 (es) |
EA (1) | EA202190914A1 (es) |
IL (1) | IL282753A (es) |
MX (1) | MX2021005303A (es) |
SG (1) | SG11202103389WA (es) |
WO (1) | WO2020094580A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022123063A2 (en) | 2020-12-11 | 2022-06-16 | Glaxosmithkline Biologicals Sa | Hyper-blebbing bacteria |
GB202211033D0 (en) | 2022-07-28 | 2022-09-14 | Glaxosmithkline Biologicals Sa | Purification process |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
ES2078258T3 (es) | 1989-04-28 | 1995-12-16 | Sclavo Spa | Mutantes de toxina pertussica, cepas de bordetella capaces de producir tales mutantes y su uso en el desarrollo de vacunas antipertussicas. |
EP2266604A3 (en) | 1998-10-16 | 2011-05-11 | GlaxoSmithKline Biologicals S.A. | Adjuvant systems and vaccines |
PT1150918E (pt) | 1999-02-03 | 2005-01-31 | Biosante Pharmaceuticals Inc | Metodo de fabrico de particulas terapeuticas de fosfato de calcio |
EP1034792A1 (en) | 1999-03-11 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Intranasal delivery of pneumococcal polysaccharide vaccines |
FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
CA2393298C (en) | 1999-12-02 | 2011-02-01 | Chiron Corporation | Compositions and methods for stabilizing biological molecules upon lyophilization |
NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
RU2323002C2 (ru) | 2001-07-26 | 2008-04-27 | Чирон Срл. | Вакцины, содержащие алюминиевые адъюванты и гистидин |
EP2255826B1 (en) * | 2002-08-02 | 2016-04-13 | GlaxoSmithKline Biologicals S.A. | Neisserial vaccine compositions comprising a combination of antigens |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
EP2802646B1 (en) * | 2011-12-21 | 2017-05-10 | Bionet-Asia Co. Ltd | Modified bordetella pertussis strains |
ES2848048T3 (es) * | 2012-10-03 | 2021-08-05 | Glaxosmithkline Biologicals Sa | Composiciones inmunogénicas |
ES2597832T3 (es) | 2013-03-08 | 2017-01-23 | Janssen Vaccines & Prevention B.V. | Vacuna acelular contra la tosferina |
AR090538A1 (es) | 2013-03-27 | 2014-11-19 | Consejo Nac Invest Cient Tec | Vacuna para la prevencion de infecciones con bordetella |
BE1022008B1 (fr) | 2013-08-05 | 2016-02-03 | Glaxosmithkline Biologicals S.A. | Compositions immunogenes combinees |
-
2019
- 2019-11-04 BR BR112021007668-9A patent/BR112021007668A2/pt unknown
- 2019-11-04 AU AU2019376832A patent/AU2019376832B2/en active Active
- 2019-11-04 AR ARP190103212A patent/AR117191A1/es unknown
- 2019-11-04 MX MX2021005303A patent/MX2021005303A/es unknown
- 2019-11-04 CN CN201980072018.3A patent/CN112996538A/zh active Pending
- 2019-11-04 JP JP2021523667A patent/JP7469302B2/ja active Active
- 2019-11-04 KR KR1020217016698A patent/KR20210090646A/ko unknown
- 2019-11-04 SG SG11202103389WA patent/SG11202103389WA/en unknown
- 2019-11-04 CA CA3117867A patent/CA3117867A1/en active Pending
- 2019-11-04 US US17/287,268 patent/US20230201325A1/en active Pending
- 2019-11-04 WO PCT/EP2019/080120 patent/WO2020094580A1/en unknown
- 2019-11-04 EP EP19805546.9A patent/EP3876982A1/en active Pending
- 2019-11-04 EA EA202190914A patent/EA202190914A1/ru unknown
-
2021
- 2021-04-28 IL IL282753A patent/IL282753A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019376832A1 (en) | 2021-05-13 |
IL282753A (en) | 2021-06-30 |
JP2022506347A (ja) | 2022-01-17 |
WO2020094580A1 (en) | 2020-05-14 |
CN112996538A (zh) | 2021-06-18 |
CA3117867A1 (en) | 2020-05-14 |
MX2021005303A (es) | 2021-07-07 |
KR20210090646A (ko) | 2021-07-20 |
AU2019376832B2 (en) | 2024-01-25 |
EP3876982A1 (en) | 2021-09-15 |
SG11202103389WA (en) | 2021-05-28 |
BR112021007668A2 (pt) | 2021-07-27 |
JP7469302B2 (ja) | 2024-04-16 |
US20230201325A1 (en) | 2023-06-29 |
EA202190914A1 (ru) | 2021-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118521T1 (el) | Συνθεση εμβολιου και μεθοδος χρησης αυτου | |
BR112018013387A2 (pt) | vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit | |
AR092896A1 (es) | Composiciones inmunogenicas | |
AR053711A1 (es) | Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion | |
ECSP22072586A (es) | VACUNA CONTRA EL VIRUS SARS-CoV-2 CON ADYUVANTE CpG | |
NO20082472L (no) | Vaksinesammensetninger omfattende en saponin adjuvant | |
BR112012004698A2 (pt) | métodos de redução de atividade virucida em composições de pcv-2 e composições de pcv-2 com uma imonugenicidade aprimorada. | |
AR090294A1 (es) | Composiciones de neisseria meningitidis y metodos de las mismas | |
AR081809A1 (es) | Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas | |
CO6321162A2 (es) | Una vacuna que comprende una cantidad inmunogenica de un antigeno en somastatina y un adyuvante | |
BR112013017171A2 (pt) | vacina de combinação imunogênica estável, processo de preparação de vacina de combinação estável, método de uso de moléculas antigênicas e método de administração a indivíduos humanos | |
NZ591950A (en) | Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition | |
AR117191A1 (es) | Composiciones inmunogénicas | |
BR112015005056A2 (pt) | vacinas de combinação com sorogrupo b meningococcus e d/t/p | |
MX2018015506A (es) | Vacuna contra virus de bronquitis infecciosa. | |
BR112015021523A2 (pt) | composição de uma vacina contra a tosse convulsa acelular, e, métodos para vacinar um sujeito contra a bordetella pertussis e para proteger um sujeito da tosse convulsa | |
GEP201706766B (en) | Methods and compositions for vaccinating against staphylococcus aureus | |
MX2023012530A (es) | Composición y metodos de vacuna adyuvada. | |
PE20211648A1 (es) | Composicion de vacuna combinada que comprende dosis reducidas del virus inactivado de la polio y metodo de preparacion de la misma | |
EA202191145A1 (ru) | Вакцина виб 4/91 с гетерологичным шиповидным белком | |
CO6341568A2 (es) | Composicion inmunologica | |
PL404247A1 (pl) | Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis | |
BR112022003698A2 (pt) | Método de tratamento de uma infecção pelo vírus da hepatite b e composição farmacêutica | |
AR088908A1 (es) | Vacuna | |
CL2022000086A1 (es) | Vacunas contra ehrlichia y composiciones inmunogénicas |